Hartwell Lauren P, Baker Annette L, Jenkins Kathy J, de Ferranti Sarah D, Saleeb Susan F
Department of Cardiology,Boston Children's Hospital,Harvard Medical School,Boston,MA,USA.
Cardiol Young. 2019 Jan;29(1):59-66. doi: 10.1017/S104795111800183X. Epub 2018 Oct 30.
The American College of Cardiology Quality Network enables national benchmarking and collaborative quality improvement through vetted metrics. We describe here our initial experience with the Quality Network.
Quarterly data for metrics pertaining to chest pain, Kawasaki disease, tetralogy of Fallot, elevated body mass index, and others were shared with the collaboratives for benchmarking. National improvement efforts focussed on counselling for elevated body mass index and 22q11.2 testing in tetralogy of Fallot. Improvement strategies included developing multi-disciplinary workgroups, educational materials, and electronic health record advances.
Chest pain metric performance was high compared with national means: obtaining family history (90-100% versus 51-77%), electrocardiogram (100% versus 89-99%), and echocardiogram for exertional complaints (95-100% versus 74-96%). Kawasaki metric performance was high, including obtaining coronary measurements (100% versus 85-97%), prescribing aspirin (100% versus 86-99%), follow-up with imaging (100% versus 85-98%), and documenting no activity restriction without coronary aneurysms (83-100% versus 64-93%). Counselling for elevated body mass index was variable (25-75% versus 31-50%) throughout quality improvement efforts. Testing for 22q11.2 deletion in tetralogy of Fallot patients was consistently above the national mean (60-85% versus 54-68%) with improved genetics data capture.
The Quality Network promotes meaningful benchmarking and collaborative quality improvement. Our high performance for chest pain and Kawasaki metrics is likely related to previous improvement efforts in chest pain management and a dedicated Kawasaki team. Uptake of counselling for elevated body mass index is variable; stronger engagement among numerous providers is needed. Recommendations for 22q11.2 testing in tetralogy of Fallot were widely recognised and implemented.
美国心脏病学会质量网络通过经过审核的指标实现全国范围内的基准对比和协作式质量改进。我们在此描述我们在质量网络方面的初步经验。
与各协作方共享有关胸痛、川崎病、法洛四联症、体重指数升高及其他指标的季度数据,用于基准对比。全国性的改进工作重点关注体重指数升高的咨询以及法洛四联症患者的22q11.2检测。改进策略包括组建多学科工作组、编写教育材料以及推进电子健康记录。
与全国平均水平相比,胸痛指标表现出色:获取家族病史(90 - 100% 对比51 - 77%)、心电图检查(100% 对比89 - 99%)以及针对劳力性不适进行超声心动图检查(95 - 100% 对比74 - 96%)。川崎病指标表现也很高,包括进行冠状动脉测量(100% 对比85 - 97%)、开具阿司匹林(100% 对比86 - 99%)、进行影像学随访(100% 对比85 - 98%)以及记录无冠状动脉瘤时无活动限制(83 - 100% 对比64 - 93%)。在整个质量改进工作中,体重指数升高的咨询情况存在差异(25 - 75% 对比31 - 50%)。法洛四联症患者的22q11.2缺失检测一直高于全国平均水平(60 - 85% 对比54 - 68%),且遗传学数据采集有所改善。
质量网络促进了有意义的基准对比和协作式质量改进。我们在胸痛和川崎病指标方面的出色表现可能与之前在胸痛管理方面的改进努力以及专门的川崎病团队有关。体重指数升高咨询的接受情况存在差异;需要众多医疗服务提供者更强有力的参与。法洛四联症患者22q11.2检测的建议得到广泛认可并得以实施。